Cause of incident
2021165438+1On October 22nd, the State Administration of Pharmaceutical Products announced that some batches of COVID-19 inactivated vaccine produced by Kexing Zhongwei Company failed the inspection. Specifically, in these batches of vaccines, the virus inactivation effect does not meet the requirements. Once the news was released, it immediately aroused widespread concern in society.
Subsequent treatment
The State Administration of Pharmaceutical Products immediately took a series of measures against unqualified vaccines produced by Kexing Zhongwei Company. First of all, the bureau asked Kexing Zhongwei Company to immediately stop producing and selling unqualified vaccines and recall the unqualified vaccines that have been produced and sold. Secondly, the bureau requires Kexing Zhongwei Company to conduct a comprehensive investigation and rectification of the problems existing in the production process, and carry out vaccine production in strict accordance with regulations to ensure the quality and safety of vaccines. At the same time, the bureau also asked Kexing Zhongwei Company to comprehensively rectify the management system, strengthen internal supervision and improve the quality management level.
impact analysis
The unqualified vaccine incident produced by Kexing Zhongwei Company is undoubtedly a huge blow to the whole vaccine industry. First of all, this incident will further strengthen people's concern about vaccine quality and safety, and have a certain impact on the overall image and reputation of the vaccine industry. Secondly, this incident will also cause certain losses and impacts on Kexing Zhongwei Company itself, including financial losses and brand image losses.